MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 585005 | Name: PF 1022A
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PF 1022A is an anthelmintic depsipeptide isolated from Mycelia Sterilia.

Chemical Structure

PF 1022A
CAS#133413-70-4

Theoretical Analysis

MedKoo Cat#: 585005

Name: PF 1022A

CAS#: 133413-70-4

Chemical Formula: C52H76N4O12

Exact Mass: 948.5460

Molecular Weight: 949.20

Elemental Analysis: C, 65.80; H, 8.07; N, 5.90; O, 20.23

Price and Availability

Size Price Availability Quantity
1mg USD 280.00 2 Weeks
5mg USD 850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
PF 1022A; PF1022A; PF-1022A
IUPAC/Chemical Name
(3S,6R,9S,12R,15S,18R,21S,24R)-6,18-Dibenzyl-3,9,15,21-tetraisobutyl-4,10,12,16,22,24-hexamethyl-1,7,13,19-tetraoxa-4,10,16,22-tetraazacyclo-tetracosane-2,5,8,11,14,17,20,23-octaone
InChi Key
YJNUXGPXJFAUQJ-LYWANRAQSA-N
InChi Code
InChI=1S/C52H76N4O12/c1-31(2)25-39-49(61)65-35(9)45(57)53(11)42(28-34(7)8)52(64)68-44(30-38-23-19-16-20-24-38)48(60)56(14)40(26-32(3)4)50(62)66-36(10)46(58)54(12)41(27-33(5)6)51(63)67-43(47(59)55(39)13)29-37-21-17-15-18-22-37/h15-24,31-36,39-44H,25-30H2,1-14H3/t35-,36-,39+,40+,41+,42+,43-,44-/m1/s1
SMILES Code
O=C([C@H](CC(C)C)N(C)C([C@@H](CC1=CC=CC=C1)OC([C@H](CC(C)C)N(C)C([C@@H](C)OC([C@H](CC(C)C)N(C)C([C@@H](CC2=CC=CC=C2)OC([C@H](CC(C)C)N3C)=O)=O)=O)=O)=O)=O)O[C@H](C)C3=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
PF 1022A is a cyclooctadepsipeptide with broadspectrum anthelmintic properties produced by fermentation of the fungus Mycelia sterilia.
In vitro activity:
This is the first study describing the effect of PF1022A on mammalian cells and tissues. Short time effects were based on cell cycle blockade in G(0)/G(1) phase. Additionally, the cell cycle and apoptosis regulating proteins p53, p21 and bax, but not Bcl-2 were shown to impact on PF1022A-induced cytotoxicity. However, since PF1022A-induced cytotoxicity was found at drug concentrations higher than those used in anthelmintic treatment, it can be suggested that PF1022A intake might not impair human or animal health. Reference: Biochem Pharmacol. 2009 Apr 15;77(8):1437-44. https://pubmed.ncbi.nlm.nih.gov/19426683/
In vivo activity:
To supplement published reports and determine potential utility of PF1022A as a ruminant anthelmintic, the compound was examined in in vitro and in vivo models. The potency of PF1022A in reducing motility is greater than commercial anthelmintics. Examination of ATP levels in PF1022A-paralyzed H. contortus indicates that worms are not killed, suggesting the compound acts as a neurotoxin in nematodes. In the jird, PF1022A has activity orally against each of the parasites studied and at doses comparable to all commercial anthelmintics, except the macrocyclic lactones which are more potent. Reference: J Antibiot (Tokyo). 1995 Aug;48(8):820-3. https://pubmed.ncbi.nlm.nih.gov/7592027/
Solvent mg/mL mM comments
Solubility
DMSO 43.0 45.30
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 949.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Nwosu U, Vargas M, Harder A, Keiser J. Efficacy of the cyclooctadepsipeptide PF1022A against Heligmosomoides bakeri in vitro and in vivo. Parasitology. 2011 Aug;138(9):1193-201. doi: 10.1017/S003118201100076X. Epub 2011 Jul 15. PMID: 21756418. 2. Dornetshuber R, Kamyar MR, Rawnduzi P, Baburin I, Kouri K, Pilz E, Hornbogen T, Zocher R, Berger W, Lemmens-Gruber R. Effects of the anthelmintic drug PF1022A on mammalian tissue and cells. Biochem Pharmacol. 2009 Apr 15;77(8):1437-44. doi: 10.1016/j.bcp.2009.01.005. Epub 2009 Jan 21. PMID: 19426683. 3. Conder GA, Johnson SS, Nowakowski DS, Blake TE, Dutton FE, Nelson SJ, Thomas EM, Davis JP, Thompson DP. Anthelmintic profile of the cyclodepsipeptide PF1022A in in vitro and in vivo models. J Antibiot (Tokyo). 1995 Aug;48(8):820-3. doi: 10.7164/antibiotics.48.820. Erratum in: J Antibiot (Tokyo) 1995 Nov;48(11):C-2. PMID: 7592027.
In vitro protocol:
1. Nwosu U, Vargas M, Harder A, Keiser J. Efficacy of the cyclooctadepsipeptide PF1022A against Heligmosomoides bakeri in vitro and in vivo. Parasitology. 2011 Aug;138(9):1193-201. doi: 10.1017/S003118201100076X. Epub 2011 Jul 15. PMID: 21756418. 2. Dornetshuber R, Kamyar MR, Rawnduzi P, Baburin I, Kouri K, Pilz E, Hornbogen T, Zocher R, Berger W, Lemmens-Gruber R. Effects of the anthelmintic drug PF1022A on mammalian tissue and cells. Biochem Pharmacol. 2009 Apr 15;77(8):1437-44. doi: 10.1016/j.bcp.2009.01.005. Epub 2009 Jan 21. PMID: 19426683.
In vivo protocol:
1. Conder GA, Johnson SS, Nowakowski DS, Blake TE, Dutton FE, Nelson SJ, Thomas EM, Davis JP, Thompson DP. Anthelmintic profile of the cyclodepsipeptide PF1022A in in vitro and in vivo models. J Antibiot (Tokyo). 1995 Aug;48(8):820-3. doi: 10.7164/antibiotics.48.820. Erratum in: J Antibiot (Tokyo) 1995 Nov;48(11):C-2. PMID: 7592027.
1: Zahner H, Taubert A, Harder A, von Samson-Himmelstjerna G. Filaricidal efficacy of anthelmintically active cyclodepsipeptides. Int J Parasitol. 2001 Nov;31(13):1515-22. PubMed PMID: 11595239. 2: von Samson-Himmelstjerna G, Harder A, Schnieder T, Kalbe J, Mencke N. In vivo activities of the new anthelmintic depsipeptide PF 1022A. Parasitol Res. 2000 Mar;86(3):194-9. PubMed PMID: 10726989. 3: Sivanathan S, Körber F, Scherkenbeck J. Semisynthetic routes to PF1022H--A precursor for new derivatives of the anthelmintic cyclooctadepsipeptide PF1022A. Bioorg Med Chem. 2016 Feb 15;24(4):873-6. doi: 10.1016/j.bmc.2016.01.014. Epub 2016 Jan 8. PubMed PMID: 26810834. 4: Jeschke P, Harder A, von Samson-Himmelstjerna G, Etzel W, Gau W, Thielking G, Bonse G. Synthesis of anthelmintically active N-methylated amidoxime analogues of the cyclic octadepsipeptide PF1022A. Pest Manag Sci. 2002 Dec;58(12):1205-15. PubMed PMID: 12476993. 5: Harder A, Schmitt-Wrede HP, Krücken J, Marinovski P, Wunderlich F, Willson J, Amliwala K, Holden-Dye L, Walker R. Cyclooctadepsipeptides--an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents. 2003 Sep;22(3):318-31. Review. PubMed PMID: 13678839. 6: Kulke D, Krücken J, Harder A, Krebber R, Fraatz K, Mehlhorn H, VON Samson-Himmelstjerna G. In vivo efficacy of PF1022A and nicotinic acetylcholine receptor agonists alone and in combination against Nippostrongylus brasiliensis. Parasitology. 2013 Sep;140(10):1252-65. doi: 10.1017/S0031182013000632. Epub 2013 Jun 7. PubMed PMID: 23742764. 7: Geary TG, Sangster NC, Thompson DP. Frontiers in anthelmintic pharmacology. Vet Parasitol. 1999 Aug 1;84(3-4):275-95. Review. PubMed PMID: 10456419. 8: Krücken J, Harder A, Jeschke P, Holden-Dye L, O'Connor V, Welz C, von Samson-Himmelstjerna G. Anthelmintic cyclcooctadepsipeptides: complex in structure and mode of action. Trends Parasitol. 2012 Sep;28(9):385-94. doi: 10.1016/j.pt.2012.06.005. Epub 2012 Jul 31. Review. PubMed PMID: 22858281. 9: Ohyama M, Okada Y, Takahashi M, Sakanaka O, Matsumoto M, Atsumi K. Structure-activity relationship of anthelmintic cyclooctadepsipeptides. Biosci Biotechnol Biochem. 2011;75(7):1354-63. Epub 2011 Jul 7. PubMed PMID: 21737929. 10: Scherkenbeck J, Jeschke P, Harder A. PF1022A and related cyclodepsipeptides - a novel class of anthelmintics. Curr Top Med Chem. 2002 Jul;2(7):759-77. Review. PubMed PMID: 12052189. 11: Harder A, von Samson-Himmelstjerna G. Cyclooctadepsipeptides--a new class of anthelmintically active compounds. Parasitol Res. 2002 Jun;88(6):481-8. Epub 2002 Mar 16. Review. PubMed PMID: 12107468. 12: Kachi S, Terada M, Hashimoto H. Effects of amorphous and polymorphs of PF1022A, a new antinematode drug, on Angiostrongylus costaricensis in mice. Jpn J Pharmacol. 1998 Jul;77(3):235-45. PubMed PMID: 9717771. 13: Lee BH, Dutton FE, Thompson DP, Thomas EM. Generation of a small library of cyclodepsipeptide PF1022A analogues using a cyclization-cleavage method with oxime resin. Bioorg Med Chem Lett. 2002 Feb 11;12(3):353-6. PubMed PMID: 11814795. 14: Jeschke R, Iinuma K, Harder A, Schindler M, Murakami T. Influence of the cyclooctadepsipeptides PF1022A and PF1022E as natural products on the design of semi-synthetic anthelmintics such as emodepside. Parasitol Res. 2005 Oct;97 Suppl 1:S11-S16. doi: 10.1007/s00436-005-1439-y. PubMed PMID: 16228266. 15: Sasaki T, Takagi M, Yaguchi T, Miyadoh S, Okada T, Koyama M. A new anthelmintic cyclodepsipeptide, PF1022A. J Antibiot (Tokyo). 1992 May;45(5):692-7. Erratum in: J Antibiot (Tokyo) 1996 Sep;49(9):C-2. PubMed PMID: 1624372. 16: Weckwerth W, Miyamoto K, Iinuma K, Krause M, Glinski M, Storm T, Bonse G, Kleinkauf H, Zocher R. Biosynthesis of PF1022A and related cyclooctadepsipeptides. J Biol Chem. 2000 Jun 9;275(23):17909-15. PubMed PMID: 10751395. 17: Dutton FE, Nelson SJ. Synthesis of PF1022A, an anthelmintic cyclodepsipeptide. J Antibiot (Tokyo). 1994 Nov;47(11):1322-7. PubMed PMID: 8002397. 18: Yanai K, Sumida N, Okakura K, Moriya T, Watanabe M, Murakami T. Para-position derivatives of fungal anthelmintic cyclodepsipeptides engineered with Streptomyces venezuelae antibiotic biosynthetic genes. Nat Biotechnol. 2004 Jul;22(7):848-55. Epub 2004 Jun 6. PubMed PMID: 15184904. 19: Conder GA, Johnson SS, Nowakowski DS, Blake TE, Dutton FE, Nelson SJ, Thomas EM, Davis JP, Thompson DP. Anthelmintic profile of the cyclodepsipeptide PF1022A in in vitro and in vivo models. J Antibiot (Tokyo). 1995 Aug;48(8):820-3. Erratum in: J Antibiot (Tokyo) 1995 Nov;48(11):C-2. PubMed PMID: 7592027. 20: Dyker H, Scherkenbeck J, Gondol D, Goehrt A, Harder A. Azadepsipeptides: synthesis and evaluation of a novel class of peptidomimetics. J Org Chem. 2001 Jun 1;66(11):3760-6. PubMed PMID: 11374995.

View History

Prisotinol dihydrochloride

Prisotinol dihydrochloride